A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Patients With HER2-Positive Early Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Pertuzumab (Primary) ; Pertuzumab/trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer; Inflammatory breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms PHranceSCa
- Sponsors Genentech; Roche
- 13 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 01 Nov 2019 Planned End Date changed from 4 Oct 2022 to 3 Nov 2022.
- 01 Feb 2019 Planned End Date changed from 22 Nov 2022 to 4 Oct 2022.